Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

• Main Authors: Marta Amigo-Basilio, Covadonga Álvarez-González, Carlos Cobo-Vázquez, Isabel Leco-Berrocal, Luis Miguel Sáez-Alcaide, Cristina Méniz-García
• Format: Article
• Language: English
• Published: MDPI AG 2021-05-01
• Series: Applied Sciences
• Subjects: target therapy; antiangiogenic agent; denosumab; osteonecrosis of the jaw; monoclonal antibody; stomatitis
• Online Access: https://www.mdpi.com/2076-3417/11/11/4865

Objective: The aim of this study is to know the biological therapy drugs that are related to adverse events, what dental treatments are associated with the appearance of these events, their severity, and how they are resolved. Study design: Analysis of cases described in the literature on patients undergoing treatment with biological therapies who have developed adverse effects associated with these drugs. Results: Of the 62 articles reviewed, 49 describe 68 cases of MRONJ, most of which appeared in the jaw and received surgical and/or conservative treatment. Conclusions: Biological therapies can potentially develop adverse effects in the oral cavity, so strict monitoring by the dentist is necessary.